In Phase C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Participants will acquire treatment until finally sickness progression or even the individuals are unable to tolerate the study drugs. There might be greater treatment burden for individuals In this particular trial https://thomasa322oak5.blogvivi.com/profile